Advertisement

Drug Treatment of Schizophrenia: State of the Art and the Potential of the Atypical Neuroleptics

  • Hans-Jürgen Möller

Abstract

Based on the multifactorial etiopathogenesis of schizophrenia, a multidimensional therapy approach is suggested, in which psychopharmacological and psychosocial methods are combined (Deister and Möller, 1998; Moller and von Zerssen, 1995). The results of controlled group studies show that the efficacy of neuroleptics is very well proven for both treatment of the acute phase and relapse prevention (Möller et al., 2000). Supportive and educational approaches to increase compliance are widely used. Information about the complex causation of the disease and about its treatment requirements and possibilities are of great importance for the patient himself and also for his relatives, among others to increase the compliance.

Keywords

Negative Symptom Schizophrenic Patient Tardive Dyskinesia Relapse Prevention Extrapyramidal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini, R.J., Cohen, B.M., and Teicher, M.H. (1988): Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45: 79–91PubMedCrossRefGoogle Scholar
  2. Barnes, T.R., and Curson, D.A. (1994): Long-term depot antipsychotics. A riskbenefit assessment. Drug Safety 10: 464–479PubMedCrossRefGoogle Scholar
  3. Bitter, I., Volavka, J., and Scheurer, J. (1991): The concept of the neuroleptic threshold: An update. Journal of Clinical Psychopharmacology 11: 28–33PubMedCrossRefGoogle Scholar
  4. Carpenter, W.T.J, Stevens, J.H., and Rey, A.C. (1992): Early intervention vs. continuous pharmacotherapy in schizophrenia. Psychopharmacological Bulletin 18: 21–23Google Scholar
  5. Carpenter, W.T.J., Heinrichs, D.W., and Alphs, L.D. (1985): Treatment of negative symptoms. Schizophrenia Bulletin 11: 440–452PubMedGoogle Scholar
  6. Cooper, S.J., Raniwalla, J., and Wilch, C. (1996): Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. European Neuropsychopharmacology 6 (Suppl. 3): p. 148CrossRefGoogle Scholar
  7. Dahl, S.G. (1986): Plasma level monitoring of antipsychotic drugs. Clinical utility. Clinical. Pharmacokinetics 11: 36–61PubMedCrossRefGoogle Scholar
  8. Deister, A., and Möller, H.J. (1998): Schizophrenie und verwandte Psychosen Stuttgart: Wissenschaftliche VerlagsgesellschaftGoogle Scholar
  9. Fleischhacker, W.W. (1999): The pharmacotherapy of schizophrenic disorders. Depressive disorders (in press)Google Scholar
  10. Fleischhacker, W.W., Meise, U., Gunther, V., and Kurtz, M. (1994): Compliance with antipsychotic treatment, influence of side-effects. Acta Psychiatrica Scandinavica 89(Suppl. 382): 11–15CrossRefGoogle Scholar
  11. Gaebel, W., and Falkai, P. (1998): Praxisleitlinien in Psychiatrie und Psychotherapie, Band 1: Behandlungsleitlinie Schizophrenie. Dentsche Gesellschaft für Psychiatrie, Psychotherapie und Nerrenheilkunde. Darmstadt: SteinkopffGoogle Scholar
  12. Gaebel, W., Frick, U., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., Pietzcker, A, and Tegeler, J. (1995): Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? British Journal of Psychiatry 163 (Suppl. 21): 8–12Google Scholar
  13. Gardos, G. (1974): Are antipsychotic drugs interchangeable? Journal of Nervous and Mental Disease 159: 343–348PubMedCrossRefGoogle Scholar
  14. Goldstein, M.J., Rodnick, E.H., Evans, J.R., May, P.R., and Steinberg, M.R. (1978): Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 35: 1169–1177PubMedCrossRefGoogle Scholar
  15. Goodnick, P.J. and Meltzer, H.Y. (1984): Treatment of schizoaffective disorders. Schizophrenia Bulletin 10: 30–48PubMedGoogle Scholar
  16. Herz, M.I., Glazer, W.M., Mostert, M.A., Sheard, M.A., Szymanski, H.V., Hafez, H., Mirza, M., and Vana, J. (1991): Intermittent vs maintenance medication in schizophrenia: Two-year results. Archives of General Psychiatry 48: 333–339PubMedCrossRefGoogle Scholar
  17. Hogarty, G.E., Ulrich, R., Goldberg, S., and Schooler, N. (1976): Sociotherapy and the prevention of relapse among schizophrenic patients: An artifact of drug? Proceedings of the Annual Meeting of the American Psychopathological Association 285–293Google Scholar
  18. Johnson, D.A.W. (1975): Observations on the dose regimens of fluphenazine decanoate in maintenance therapy of schizophrenia. British Journal of Psychiatry 126: 457–461PubMedCrossRefGoogle Scholar
  19. Jolley, A.G., Hirsch, S.R., Morrison, E., McRink, A., and Wilson, L. (1990): Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. British Journal of Medicine 301: 837–842CrossRefGoogle Scholar
  20. Kane, J.M., Honigfeld, G., Singer, J., and Meltzer, H.Y. (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry 48: 789–796CrossRefGoogle Scholar
  21. Kane, J.M. and Marder, S.R. (1993): Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin 19: 287–302PubMedGoogle Scholar
  22. Kane, J.M., Moller, H.J., and Awouters, F. (1996): Serotonin in antipsychotic treatment - Mechanisms and clinical practice. New York Basel Hong Kong: Marcel DekkerGoogle Scholar
  23. Kane, J.M., Rifkin, A., Woerner, M., Reardon, G., Sarantakos, S., Schiebel, D., and Ramos Lorenzi, J. (1983): Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry 40: 893–896PubMedCrossRefGoogle Scholar
  24. Kane, J.M., Woerner, M., Borenstein, M., Wegner, J., and Lieberman, J. (1986): Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacological Bulletin 22: 254–258Google Scholar
  25. Kinon, B.J., Kane, J.M., Johns, C., Perovich, R, Ismi, M., Koreen, A., and Weiden, P. (1993): Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacological Bulletin 29: 309–314Google Scholar
  26. Kissling, W. (1994): Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica 89 (Suppl. 382): 16–24CrossRefGoogle Scholar
  27. Klemm, E., Grünwald, F., Kasper, S., Menzel, C., Broich, K., Danos, P., Reichmann, K., Krappel, C., Rieker, O., Briele, B., Hotze, A.L., Möller, H.J., and Biersack, H.J. (1996): IBZM SPECT for imaging of striatal D2 Dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry 153: 183–190PubMedGoogle Scholar
  28. Krystal, J., D’Souza, D.C., Holgate, K.L., Staser, J.A, Silber, C.J., and Mack, R.J. (1997): Sertindole: A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life in stable schizophrenic patients. Paper presented at the 10th ECNP, ViennaGoogle Scholar
  29. Lieberman, J., Jody, D., Geisler, S., Alvir, J., Loebel, A., Szymanski, S., Woerner, M., and Borenstein, M. (1993): Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50: 369–376PubMedCrossRefGoogle Scholar
  30. Loo, H., Poirier, L.M., Theron, M., Rein, W., and Fleurot, O. (1997): Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry 170: 18–22PubMedCrossRefGoogle Scholar
  31. Marder, S.R. and Meibach, R.C. (1994): Risperidone in the treatment of schizophrenia. American Journal Psychiatry 151: 825–835Google Scholar
  32. Marder, S.R, Van, P.T., Mintz, J., Lebell, M., McKenzie, J., and May, P.R. (1987): Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Archives of General Psychiatry 44: 518–521PubMedCrossRefGoogle Scholar
  33. McEvoy, J.P., Hogarty, G.E., and Steingard, S. (1991): Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 48: 739–745PubMedCrossRefGoogle Scholar
  34. Meltzer, H.Y. (1992): Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 18: 515–542PubMedGoogle Scholar
  35. Meltzer, H.Y., Bastani, B., Kwon, K.Y., Ramirez, L.F., Burnett, S., and Sharpe, J. (1989): A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Suppl. 99), S68–S72Google Scholar
  36. Möller, H.-J. (1999a): Atypical antipsychotics: a new approach in the treatment of negative symptoms? European Archives of Psychiatry and Clinical Neuroscience 249 (Suppl. 4): IV99–IVI07CrossRefGoogle Scholar
  37. Möller, H.-J. (1999b): State of evaluation and clinical benefits of atypical neuroleptics. The treatment of schizophrenia: Status and emerging trends. (Brenner, H.D. Böker, W. and Genner, R., eds.), Göttingen Seattle Toronto: Hogrefe and HuberGoogle Scholar
  38. Möller, H.-J., Müller, N., and Bandelow, B. (2000): Neuroleptika. Stuttgart: Wissenschaftliche VerlagsgesellschaftGoogle Scholar
  39. Möller, H.-J., and Rao, M.L. (1996): Negative symptoms of schizophrenia: Methodological issues, biochemical findings and efficacy of neuroleptic treatment. In: Implications of psychopharmacology to psychiatry. Biological, nosological, and therapeutical concepts (Ackenheil, M., Bondy, B., Engel, R., Ermann, M., and Nedopil, N., eds.), pp. 158–178. Berlin Heidelberg New York: SpringerCrossRefGoogle Scholar
  40. Möller, H.-J. (1990): Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Leitlinien neuroleptischer Therapie (Heinrich, K., ed.), pp. 97–115: Berlin Heidelberg New York: SpringerCrossRefGoogle Scholar
  41. Möller, H.-J. (1992): Neuroleptische Rezidivprophylaxe und Langzeitbehandlung schizophrener Psychosen. In: Neuroleptika, pp. 153–168. Wien: SpringerGoogle Scholar
  42. Möller, H.J. (1993): Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. European Neuropsychopharmacology 3: 1–11PubMedCrossRefGoogle Scholar
  43. Möller, H.J. (1995): Extrapyramidal side effects of neuroleptic medication: focus on risperidone. In: Critical issues in the treatment of schizophrenia (Brunello, N., Racagni, G., Langer, S.Z., and Mendlewicz, J., eds.). pp. 142–151. Basel: KargerGoogle Scholar
  44. Möller, H.J. (1997): Atypische Neuroleptika: 1st der Begriff gerechtfertigt? Psychopharmakotherapie 4: 130–132.Google Scholar
  45. Möller, H.J., Bauml, J., Ferrero, F., Fuger, J., Geretsegger, C., Kasper, S., Kissling, W., and Schubert, H. (1997): Risperidone in the treatment of schizophrenia: Results of a study of patients from Germany, Austria, and Switzerland. European Archives of Psychiatry and Clinical Neuroscience 247: 291–296PubMedCrossRefGoogle Scholar
  46. Möller, H.J., Kissling, W., Lang, C., Doerr, P., Pirke, K.M., and von Zerssen, D. (1982): Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. American Journal of Psychiatry 139: 1571–1575PubMedGoogle Scholar
  47. Möller, H.J., and Morin, C. (1989): Behandlung schizodepressiver Syndrome mit Antidepressiva. In: Schizoaffektive Psychosen. Diagnose, Therapie und Prophylaxe (Marneros, A., ed.), pp. 159–178. Berlin Heidelberg New York: SpringerGoogle Scholar
  48. Möller, H.J., van Praag, H.M., Aufdembrinke, B., Bailey, P., Barnes, T.R., Beck, J., Bentsen, H., Eich, F.X., Farrow, L., Fleischhacker, W.W., Gerlach, J., Grafford, K., Hentschel, B., Hertkorn, A., Heylen, S., Lecrubier, Y., Leonhard, J.P., McKenna, P., Maier, W., Pedersen, V., Rappard, A., Rein, W., Ryan, J., Sloth Nielsen, M., Stieglitz, R.D., Wegener, G., and Wilson, J. (1994): Negative symptoms in schizophrenia: Considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115: 221–228PubMedCrossRefGoogle Scholar
  49. Möller, H.J., and von Zerssen, D. (1995): Course and outcome of schizophrenia. In: Schizophrenia (Hirsch, S.R and Weinberger, D.R., eds.), pp. 107–127. Oxford: Blackwell ScienceGoogle Scholar
  50. Nordstrom, A.-L., Farde, L., and Wiesel, F.A. (1993): Central D - dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biological Psychiatry 33: 227–235PubMedCrossRefGoogle Scholar
  51. Northoff, G., Wenke, J., Demisch, L., Eckert, J., Gille, B., and Pflug, B. (1995): Catatonia: short-term response to lorazepam and dopaminergic metabolism. Psychopharmacology 122: 182–186PubMedCrossRefGoogle Scholar
  52. Petit, M., Raniwalla, J., Tweed, J., Leutenegger, E., Dollfus, S., and Kelly, F. (1996): A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial. Psychopharmacological Bulletin 32: 81–87Google Scholar
  53. Peuskens, J. (1995): Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. British Journal of Psychiatry 166: 712–726PubMedCrossRefGoogle Scholar
  54. Prusoff, B.A., Williams, D.H., Weissman, M.M., and Astrachan, B.A. (1979): Treatment of secondary depression in schizophrenia. Archives of General Psychiatry 36: 569–575PubMedCrossRefGoogle Scholar
  55. Reardon, G.T., Rifkin, A., Schwartz, A., Myerson, A., and Siris, S.G. (1989): Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry 146: 726–729PubMedGoogle Scholar
  56. Rifkin, A., Doddi, S., Karajgi, B., Borenstein, M., and Wachpress, M. (1991): Dosage of haloperidol for schizophrenia. Archives of General Psychiatry 48: 166–170PubMedCrossRefGoogle Scholar
  57. Rosebush, P.I., Hildebrand, A.M., Furlong, B.G., and Mazurek, M.F. (1990): Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Journal of Clinical Psychiatry 51: 357–362PubMedGoogle Scholar
  58. Sagatovic, M., and Meltzer, H.Y. (1993): The effect of short-term electroconvulsive treatment plus neuroleptic in treatment-resistant schizophrenia and schizoaffective disorder. Convulsive Therapy 9: 167–175Google Scholar
  59. Satterlee, W., Dellva, M.A., Beasley, C., Tran, P., and Tollefson, G. (1996): Effectiveness of olanzapine in long-term continuation treatment. Psychopharmacological Bulletin 32: 509Google Scholar
  60. Schulz, S.C., Kahn, E.M., Baker, R.W., and Conley, R.R. (1990): Lithium and Carbamazepine. Augmentation in treatment-refractory schizophrenia. In: The neuroleptic-nonresponsive patient: Characterization and treatment (Angrist, B. and Schulz, S.C., eds.), pp. 111–136. Washington London: American Psychiatric PressGoogle Scholar
  61. Shalev, A., Hermesh, H., Rothberg, J., and Munitz, H. (1993): Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 87: 86–91PubMedCrossRefGoogle Scholar
  62. Siris, S.G. (1995): Depression and schizophrenia. In: Schizophrenia (Hirsch, S.R. and Weinberger, D.R., eds.), pp. 128–145. Oxford: Blackwell ScienceGoogle Scholar
  63. Siris, S.G., Kammen, v.P., and Docherty, J.P. (1978): Use of antidepressant drugs in schizophrenia. Archives of General Psychiatry 35: 1368–1377PubMedCrossRefGoogle Scholar
  64. Street, J.S., Tamura, R., Sanger, T., and Tollefson, G. (1996): Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Psychopharmacological Bulletin 32: 522Google Scholar
  65. Tollefson, G.D., Beasley C., Tran, P.V., Street, J.S., Krueger, J.A, Tamura, R.N., Graffeo, K.A, and Thieme, M.E. (1997): Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154: 457–465PubMedGoogle Scholar
  66. Tollefson, G.D. and Sanger, T.M. (1997): Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry 154: 466–474PubMedGoogle Scholar
  67. Tollefson, G.D., Sanger, T.M., Lu, Y., and Thieme, M.E. (1998): Depresive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry 55: 250–258PubMedCrossRefGoogle Scholar
  68. Tran, P., Beasley, C. and Tollefson, G. (1996): Acute and long-term results of the dose ranging double-blind olanzapine trial. MelbourneGoogle Scholar
  69. Ungvari, G.S., Leung, C.M. and Chiu, H.M. (1994): Lorazepam in stupor. British Journal Clinical Practise 48: 165–166Google Scholar
  70. Van, P.T., Marder, S.R., and Mintz, J. (1990): A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry 47: 754–758CrossRefGoogle Scholar
  71. Walden, J. and Grunze, H. (1998): Bipolare affektive Storungen: Ursachen und Behandlung. Stuttgart New York: ThiemeGoogle Scholar
  72. Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J., Sebree, T.B., Wallin, B.A., and Kashkin, K.B. (1997): Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. American Journal of Psychiatry 154: 782–791PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • Hans-Jürgen Möller

There are no affiliations available

Personalised recommendations